10-Q/A: Iris Acquisition Corp Restates Financials Due to Related Party Transaction and Material Weakness

Iris Acquisition Corp restated its financials for the period ended September 30, 2024, due to an undisclosed related party transaction and the identification of a material weakness in internal control over financial reporting.

Summary

• Iris Acquisition Corp is filing an amendment to its Form 10-Q for the period ended September 30, 2024, to restate its unaudited condensed consolidated financial statements.
• The restatement is due to a material related party transaction involving a loan of approximately $1.216 million from Hana Immunotherapeutics LLC, an affiliate of Liminatus Pharma's CEO, to Gaius Investment Partners, the buyer of the Sponsor's managing member.
• The company also identified an additional material weakness in internal control over financial reporting, leading to the conclusion that management's report on the effectiveness of internal control as of December 31, 2023, should no longer be relied upon.
• Management also concluded that the company's disclosure controls and procedures were not effective as of September 30, 2024, due to this material weakness.
• The company's securities are now trading on the OTC Pink Marketplace under the symbols IRAAU, IRAA, and IRAAW after being delisted from Nasdaq.
• The company had $358,181 of cash in its operating bank account as of September 30, 2024.
• The company had a working capital deficit of approximately $7,141,435 as of September 30, 2024.
• The company's net loss for the three months ended September 30, 2024, was $642,900.
• The company's net loss for the nine months ended September 30, 2024, was $2,035,985.
• The company has extended the time to complete the initial Business Combination to December 31, 2024.
• The company has a Business Combination Agreement with Liminatus Pharma, LLC, which has been amended multiple times, with the latest amendment extending the termination date to December 31, 2024.
• The company's management has determined that the company's ability to continue as a going concern is in substantial doubt.
• The company has recorded $18,029 of excise tax liability calculated as 1% of the fair market value of the shares redeemed on March 7, 2024 and September 5, 2024.

Sentiment

Score: 3

Explanation: The document contains several negative aspects, including a restatement, material weakness, delisting, working capital deficit, net loss, and going concern uncertainty. While there are some positive aspects, the overall sentiment is negative.

Positives

• The company is actively working to remediate the identified material weaknesses in internal control over financial reporting.
• The company has amended the Business Combination Agreement with Liminatus Pharma, LLC, extending the termination date to December 31, 2024, providing more time to complete the transaction.
• The company has secured a PIPE Equity Investment of $15,000,000 to support the Business Combination.

Negatives

• The company is restating its financial statements due to a material related party transaction.
• A material weakness in internal control over financial reporting has been identified.
• The company's securities have been delisted from Nasdaq and are now trading on the OTC Pink Marketplace.
• The company has a significant working capital deficit of approximately $7,141,435.
• The company has incurred a net loss of $2,035,985 for the nine months ended September 30, 2024.
• The company's management has expressed substantial doubt about the company's ability to continue as a going concern.
• The company has recorded $18,029 of excise tax liability calculated as 1% of the fair market value of the shares redeemed on March 7, 2024 and September 5, 2024.

Risks

• The company's ability to complete the Business Combination with Liminatus Pharma, LLC, is uncertain.
• The company may need to obtain additional financing to complete the Business Combination or to meet its obligations after the Business Combination.
• The company's failure to complete the Business Combination by December 31, 2024, will force it to cease operations and liquidate the Trust Account.
• The company's internal control over financial reporting is not effective.
• The company's securities are trading on the OTC Pink Marketplace, which may result in lower liquidity and higher volatility.
• The company is subject to a 1% excise tax on certain stock repurchases, which could reduce the value of the company's Class A common stock.
• The company is currently evaluating its options with respect to payment of this obligation. As the Company was unable to timely pay its obligation in full, it will be subject to additional interest and penalties which are currently estimated at 10% interest per annum and a 5% underpayment penalty per month or a portion of a month up to 25% of the total liability for any amount that is unpaid from November 1, 2024, until paid in full.

Future Outlook

The company's ability to continue as a going concern is dependent on completing a Business Combination by December 31, 2024. If the company is unable to do so, it will cease operations and liquidate the Trust Account.

Management Comments

• Management has determined that if the Company is unable to complete a Business Combination by December 31, 2024, then the Company will cease all operations except for the purpose of liquidating.
• Management believes that the condensed financial statements contained in this quarterly report fairly present our financial position, results of operations and cash flows for the years covered hereby in all material respects.

Industry Context

The SPAC market has seen increased scrutiny and regulatory changes, leading to more restatements and deal terminations. This announcement reflects the challenges faced by SPACs in the current environment.

Comparison to Industry Standards

• Compared to other SPACs, Iris Acquisition Corp's restatement and material weakness disclosure are not uncommon, as many SPACs have faced similar issues related to accounting for complex financial instruments and internal controls.
• Several SPACs, such as DiamondPeak Holdings and VectoIQ Acquisition Corp, have also restated their financials due to warrant accounting issues.
• The delisting from Nasdaq is a significant setback, as it reduces the company's visibility and liquidity, similar to what happened with companies like China Xiangtai Food Co., Ltd after their delisting.

Related Party Transactions

• The restatement is due to a material related party transaction involving a loan of approximately $1.216 million from Hana Immunotherapeutics LLC, an affiliate of Liminatus Pharma's CEO, to Gaius Investment Partners, the buyer of the Sponsor's managing member.
• On July 24, 2024, Hana Immunotherapeutics, LLC, an affiliate of Chris Kim, the Chief Executive Officer of Liminatus, agreed to loan Gaius Investment Partners (Gaius), the buyer of the managing member of the Companys Sponsor, Columbass Limited (Columbass), approximately $1.216 million to facilitate Gaius acquisition of Columbass.

Stakeholder Impact

• Shareholders: The restatement, delisting, and going concern uncertainty negatively impact shareholder value.
• Employees: The uncertainty surrounding the company's future may create anxiety among employees.
• Creditors: The company's financial difficulties may increase the risk for creditors.
• Target Company (Liminatus Pharma): The delays and uncertainties surrounding the Business Combination may negatively impact Liminatus Pharma's plans.

Next Steps

• The company needs to complete the Business Combination with Liminatus Pharma, LLC, by December 31, 2024.
• The company needs to remediate the identified material weaknesses in internal control over financial reporting.
• The company needs to evaluate its options with respect to payment of the excise tax obligation.

Key Dates